880488-73-3 Usage
Uses
Used in Pharmaceutical Industry:
1(2H)-Phthalazinone, 6-bromo-4-[[1-(1,1-dimethylethyl)-3-methyl-1H-pyrazol-5-yl]amino]-2-[4-(1,1-dimethylethyl)phenyl]is used as a potential pharmaceutical compound for [application reason], such as targeting specific biological pathways or receptors due to its unique structural features.
Used in Chemical Industry:
In the chemical industry, 1(2H)-Phthalazinone, 6-bromo-4-[[1-(1,1-dimethylethyl)-3-methyl-1H-pyrazol-5-yl]amino]-2-[4-(1,1-dimethylethyl)phenyl]may be utilized as a building block or intermediate in the synthesis of other complex molecules, taking advantage of its diverse functional groups and structural components.
Check Digit Verification of cas no
The CAS Registry Mumber 880488-73-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,0,4,8 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 880488-73:
(8*8)+(7*8)+(6*0)+(5*4)+(4*8)+(3*8)+(2*7)+(1*3)=213
213 % 10 = 3
So 880488-73-3 is a valid CAS Registry Number.
880488-73-3Relevant academic research and scientific papers
Methods of inhibiting BTK and SYK protein kinases
-
Page/Page column 60, (2008/06/13)
Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.
NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS
-
Page/Page column 213, (2008/06/13)
Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.